Ryuichi Noguchi Selected Research

CDAA (Randox)

11/2017	Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development.
10/2016	DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis.
3/2015	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
11/2013	Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
7/2013	Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis.
5/2009	Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.
11/2007	Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in rats.
7/2003	Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development.
7/2002	Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryuichi Noguchi Research Topics

Disease

40	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 07/2002
25	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 04/2002
22	Neoplasms (Cancer) 10/2020 - 04/2002
20	Fibrosis (Cirrhosis) 01/2022 - 07/2002
9	Carcinogenesis 03/2020 - 07/2002
9	Fatty Liver 03/2020 - 10/2006
8	Alcoholic Fatty Liver 02/2016 - 07/2008
7	Non-alcoholic Fatty Liver Disease 11/2021 - 10/2006
5	Liver Diseases (Liver Disease) 01/2020 - 01/2009
5	Insulin Resistance 08/2013 - 01/2009
4	Chronic Hepatitis C 12/2014 - 02/2005
3	Infections 03/2022 - 05/2013
3	Acute Liver Failure (Fulminant Hepatic Failure) 03/2011 - 07/2006
2	Pleural Effusion (Pleural Effusions) 03/2022 - 08/2017
2	Ascites 03/2022 - 08/2017
2	Chronic Hepatitis B 08/2020 - 09/2017
2	Hepatitis C 01/2018 - 08/2017
2	Type 2 Diabetes Mellitus (MODY) 11/2017 - 02/2016
2	Obesity 08/2013 - 01/2009
2	Inflammation (Inflammations) 01/2013 - 05/2012
2	Eosinophilia 05/2012 - 07/2007
1	Edema (Dropsy) 03/2022
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 03/2022
1	Hypoalbuminemia 03/2022
1	Duodenal Ulcer (Curling's Ulcer) 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2020

Drug/Important Bio-Agent (IBA)

19	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2019 - 04/2002
19	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2012 - 06/2002
13	Amino Acids FDA Link 03/2020 - 07/2002
12	Choline (Choline Chloride)IBA 03/2020 - 07/2002
11	InterferonsIBA 09/2018 - 02/2005
9	CDAA (Randox)IBA 11/2017 - 07/2002
9	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 08/2010 - 12/2003
8	Angiotensin IIIBA 11/2017 - 09/2003
8	Perindopril FDA LinkGeneric 11/2006 - 06/2002
7	CollagenIBA 10/2020 - 07/2002
6	Angiotensin II Type 1 Receptor BlockersIBA 01/2022 - 05/2009
6	Glutathione Transferase (Glutathione S-Transferase)IBA 11/2013 - 07/2003
5	Losartan (Cozaar)FDA LinkGeneric 01/2022 - 05/2009
5	Biomarkers (Surrogate Marker)IBA 08/2020 - 07/2003
5	Messenger RNA (mRNA)IBA 11/2017 - 04/2002
5	Pharmaceutical PreparationsIBA 03/2014 - 02/2007
5	Branched-Chain Amino AcidsIBA 08/2013 - 01/2009
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2021 - 09/2017
4	AldosteroneIBA 08/2017 - 05/2010
4	Transforming Growth Factor beta (TGF-beta)IBA 12/2016 - 05/2006
4	EnzymesIBA 11/2013 - 07/2002
4	Vitamin K FDA Link 05/2011 - 01/2007
4	Imatinib Mesylate (Gleevec)FDA Link 04/2009 - 05/2005
3	Carrier Proteins (Binding Protein)IBA 10/2021 - 09/2017
3	CytokinesIBA 01/2013 - 05/2006
3	Chelating AgentsIBA 06/2011 - 09/2003
3	Vitamin K 2 (Vitamin K2)IBA 08/2009 - 01/2006
3	Hydroxyproline (4 Hydroxyproline)IBA 05/2005 - 07/2002
3	Tissue Inhibitor of Metalloproteinase-1IBA 09/2003 - 10/2002
2	SteroidsIBA 03/2022 - 05/2012
2	Proteins (Proteins, Gene)FDA Link 03/2022 - 11/2007
2	Hyaluronic Acid (Hyaluronan)IBA 10/2021 - 08/2020
2	Tissue Inhibitor of MetalloproteinasesIBA 10/2021 - 08/2020
2	Collagen Type IV (Type IV Collagen)IBA 10/2021 - 02/2016
2	Collagen Type III (Type III Collagen)IBA 10/2021 - 08/2020
2	Antiviral Agents (Antivirals)IBA 08/2020 - 01/2018
2	Glucose (Dextrose)FDA LinkGeneric 03/2020 - 11/2017
2	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2017 - 02/2016
2	Therapeutic UsesIBA 11/2017 - 01/2008
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 09/2017 - 06/2002
2	Alanine Transaminase (SGPT)IBA 09/2017 - 11/2006
2	ReninIBA 08/2017 - 11/2013
2	Anti-Bacterial Agents (Antibiotics)IBA 03/2015 - 05/2013
2	EndotoxinsIBA 03/2015 - 01/2013
2	Ribavirin (Virazole)FDA LinkGeneric 12/2014 - 07/2011
2	Sorafenib (BAY 43-9006)FDA Link 10/2014 - 05/2012
2	Angiotensin Receptor AntagonistsIBA 10/2014 - 07/2011
2	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2014 - 01/2012
2	Angiogenesis InhibitorsIBA 05/2011 - 02/2007
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2010 - 05/2005
2	Tumor Biomarkers (Tumor Markers)IBA 01/2009 - 06/2007
2	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 12/2008 - 07/2002
2	Biological ProductsIBA 11/2007 - 11/2004
2	Trientine (Trien)FDA Link 07/2005 - 09/2003
2	CopperIBA 07/2005 - 09/2003
2	Protein Kinase CIBA 05/2005 - 09/2003
2	Interferon-betaIBA 02/2005 - 12/2003
2	Matrix Metalloproteinases (MMPs)IBA 06/2003 - 10/2002
1	Blood Proteins (Serum Proteins)IBA 03/2022
1	Azathioprine (Imuran)FDA LinkGeneric 03/2022
1	Immunosuppressive Agents (Immunosuppressants)IBA 03/2022
1	Toll-Like Receptor 4IBA 01/2022
1	obeticholic acidIBA 01/2022
1	LipopolysaccharidesIBA 01/2022
1	SE5-OHIBA 11/2021
1	EquolIBA 11/2021
1	nasIBA 11/2021
1	Peptides (Polypeptides)IBA 10/2021
1	olmesartanIBA 01/2021
1	Plasminogen Activators (Plasminogen Activator)IBA 10/2020

Therapy/Procedure

19	Therapeutics 03/2022 - 11/2004
6	Chemoprevention 10/2014 - 11/2004
1	Radiofrequency Ablation 01/2022
1	Intraperitoneal Injections 10/2020